Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humana Inc. (NYSE: HUM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q as they are filed with the U.S. Securities and Exchange Commission. As a major participant in Medicare Advantage, Medicaid managed care and related health insurance lines, Humana uses these filings to report financial results, guidance, leadership changes and other material events.
Recent Form 8-K filings for Humana include Regulation FD disclosures reaffirming earnings guidance and providing reconciliations between GAAP earnings per common share and Adjusted earnings per common share (Adjusted EPS), which management uses to analyze core operating performance and inform planning and incentive compensation. Other 8-Ks describe results of operations for specific quarters, preliminary Medicare Advantage Star Ratings information, and leadership transitions in the insurance segment, such as the planned retirement of an Insurance Segment President and the appointment of new leaders for Medicare Advantage and the broader insurance business.
Filings also reflect Humana’s role as a health insurer and managed care organization. AM Best’s rating actions, while separate from SEC filings, complement the picture provided in regulatory reports by describing the financial strength and business profile of Humana’s health and dental insurance subsidiaries, collectively known as Humana Health Group, and by noting the contribution of the CenterWell segment as a non-insurance source of revenue and earnings.
On Stock Titan, investors and researchers can use AI-powered summaries to quickly interpret lengthy documents such as 10-K and 10-Q reports, focusing on topics that matter for a company like Humana: Medicare Advantage and Medicaid performance, Star Ratings dynamics, non-GAAP metrics like Adjusted EPS, capital structure, and risk disclosures. The filings page also surfaces insider and executive-related disclosures reported on Form 8-K, helping users track leadership changes and compensation-related arrangements referenced in those reports. Real-time updates from EDGAR combined with AI explanations make it easier to follow how Humana communicates its financial condition, strategic initiatives and regulatory developments over time.
Humana Inc. reported first quarter 2026 revenue of $39.6 billion, up from $32.1 billion a year earlier, with GAAP diluted EPS of $9.83 versus $10.30 and Adjusted EPS of $10.31 versus $11.58. The Insurance segment benefit ratio was 89.4%, slightly better than guidance of “just under 90%,” while the consolidated operating cost ratio improved to 10.2% (10.0% Adjusted). Operating cash flow rose to $1.25 billion from $331 million. For full-year 2026, Humana cut GAAP EPS guidance to at least $8.36 from $8.89 but reaffirmed Adjusted EPS guidance of at least $9.00 and expects individual Medicare Advantage membership to grow about 25%. The CenterWell segment delivered revenue growth to $6.1 billion but faced higher operating cost ratios as it absorbed recent acquisitions and risk-model changes.
Humana Inc. director Robert Stuart Field filed an initial Form 3 reporting his beneficial ownership of Humana Common stock. The filing shows a holding entry dated April 16, 2026 with 0 shares of Humana Common held directly after the reported event, and no buy or sell transactions.
Humana Inc. held its annual shareholder meeting on April 16, 2026, where all ten director nominees were elected to the board. A quorum was present, with 107,941,773 common shares represented by valid proxy.
Shareholders approved the ratification of PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, supported the non-binding advisory vote on executive compensation, and approved the Humana Inc. 2026 Stock Incentive Plan. A shareholder proposal seeking a shareholder approval requirement for excessive golden parachutes did not pass.
Humana Inc. expanded its Board of Directors from ten to eleven members and elected Robert S. Field as a director, effective immediately following the Company’s 2026 Annual Meeting of Stockholders on April 16, 2026.
The Board determined that Field qualifies as an independent director under New York Stock Exchange standards. He will participate in Humana’s standard director compensation program and receive restricted stock units in connection with his election. Field is Principal and Managing Member of ηMed Capital Management LLC and brings more than two decades of healthcare investment, strategy, and legal experience. His appointment followed a Board-led search process informed by shareholder engagement.
Humana Inc. President, CenterWell, Sanjay K. Shetty reported equity compensation activity. On April 1, 2026, he acquired 887 shares of Humana common stock through the exercise or settlement of performance-related equity awards. On the same date, 401 shares at $175.44 per share were withheld to cover tax liabilities on performance stock vesting, with no sale proceeds received.
After these transactions, Shetty directly owns 12,143 Humana common shares, which include 8,818 restricted stock units and additional Performance Stock Units. He also holds stock options over 3,964 underlying shares at an exercise price of $487.1602 expiring on April 1, 2030, and options over 6,572 underlying shares at $367.21 expiring on February 21, 2031.
Humana Inc. President, Insurance George Renaudin reported routine compensation-related activity, including an annual contribution of 25 Phantom Stock Units based on Humana common stock at $173.39 per unit under the Humana Retirement Equalization Plan.
Following the update, he holds 199 Phantom Stock Units indirectly, 16,075 shares of Humana common stock directly and 542 shares indirectly through a retirement savings plan. He also holds stock options on 4,162 shares at an exercise price of $510.2425 expiring in 2030 and options on 6,966 shares at $367.21 expiring in 2031, plus 9,059 restricted stock units that may convert into common shares.
HILZINGER KURT J reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Kurt J. Hilzinger received a grant of 536 Restricted Stock Units on Humana Common stock as compensation. The units were valued at $170.6605 per unit and are deferred until his service as a director ends, when they will settle 1-for-1 in common shares.
Footnotes explain that his annual director fees, certain cash fees, and related dividends are taken in stock units and dividend-equivalent units, all deferred into Humana common stock. He also holds additional deferred stock units and 19,448 Humana common shares directly.
Humana Inc — Schedule 13G/A (Amendment No. 11)
The Vanguard Group filed an amendment disclosing that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries and business divisions will report beneficial ownership separately. The filing states The Vanguard Group beneficially owns 0 shares of Humana Inc common stock and reports 0% ownership, with no sole or shared voting or dispositive power.
Humana Inc. completed a public offering of $1.0 billion aggregate principal amount of 6.625% fixed-to-fixed rate junior subordinated notes due 2056. The notes were sold at 100% of principal under an effective shelf registration with several major banks as joint bookrunners.
The notes pay interest at 6.625% annually until September 15, 2031, then reset every five years to the Five-year U.S. Treasury Rate plus 2.891%, with a floor of 6.625%. Interest is payable each March 15 and September 15, and Humana may defer interest for up to 10 consecutive years if no event of default exists. The securities are unsecured and junior to Humana’s senior indebtedness, effectively junior to secured debt and subsidiary liabilities. Humana expects net proceeds of about $986 million, to be used for general corporate purposes, including potential repayment of existing debt and commercial paper.